Table of Contents The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis Nippon India PHARMA Fund - G
Scheme Objective
CAGR
return of 21.1% since its launch. Ranked 35 in Sectoral
category. Return for 2023 was 39.2% , 2022 was -9.9% and 2021 was 23.9% . NAV as on 19 Nov 24 ₹499.194 ↑ 4.57 (0.92 %) Net Assets (AUM) as on 31 Oct 2024 ₹8,689 Cr. Launch Date 5 Jun 2004 Category Equity - Sectoral Rating ☆☆ Type Open Ended Fund Risk High AMC Nippon Life Asset Management Ltd. Alpha Ratio -3.51 Expense Ratio 1.88 % Sharpe Ratio 2.626 Information Ratio -0.47 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹100 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 19 Nov 24 Duration Returns 1 Month -4.6% 3 Month 0.1% 6 Month 14.9% 1 Year 35.7% 3 Year 18.3% 5 Year 27.4% 10 Year 15 Year Since launch 21.1% Historical Annual Returns
Year Returns 2023 39.2% 2022 -9.9% 2021 23.9% 2020 66.4% 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% 2015 19.4% Growth of 10k Over Years
Date Value 31 Oct 19 ₹10,000 31 Oct 20 ₹14,942 31 Oct 21 ₹20,150 31 Oct 22 ₹19,522 31 Oct 23 ₹22,948 31 Oct 24 ₹34,675 Asset Allocation
Asset Class Value Cash 4.43% Equity 95.57% Sector Allocation
Sector Value Health Care 95.57% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMADrug Manufacturers - Specialty & Generic 14% ₹1,212 Cr 6,556,349 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLABDrug Manufacturers - Specialty & Generic 9% ₹796 Cr 1,350,808 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257Drug Manufacturers - Specialty & Generic 8% ₹701 Cr 3,203,676 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087Drug Manufacturers - General 6% ₹481 Cr 3,100,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSPMedical Care Facilities 5% ₹456 Cr 648,795 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDYDrug Manufacturers - Specialty & Generic 5% ₹446 Cr 3,500,150 Vijaya Diagnostic Centre Ltd (Healthcare)
Equity, Since 30 Sep 21 | 543350Diagnostics & Research 3% ₹302 Cr 3,027,149 Ajanta Pharma Ltd (Healthcare)
Equity, Since 30 Apr 22 | 532331Drug Manufacturers - Specialty & Generic 3% ₹294 Cr 959,323 J.B. Chemicals & Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Jan 22 | JBCHEPHARMDrug Manufacturers - Specialty & Generic 3% ₹251 Cr 1,278,814 Abbott India Ltd (Healthcare)
Equity, Since 31 May 11 | ABBOTINDIADrug Manufacturers - General 3% ₹250 Cr 86,390
Talk to our investment specialistFund Managers
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 19.6 Yr. Kinjal Desai 25 May 18 6.44 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
KFin Technologies Ltd Address 138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat FAX N.A Email N.A Administrator Companies
Company Address Nippon India Mutual Fund 9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051 Auditors
Company Address Haribhakti & Co. Chartered Accountants 42, Free Press House,4th Floor,,215, Nariman Point, All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year Nippon India Pharma Fund
Normal Dividend, Payout ₹127.096
↑ 1.16 14.93 % 34.69 % 19.67 % 30.01 % Nippon India Pharma Fund
Normal Dividend, Reinvestment ₹127.096
↑ 1.16 14.93 % 34.69 % 19.67 % 30.01 % Nippon India Pharma Fund
Growth ₹499.194
↑ 4.57 14.93 % 35.69 % 18.27 % 27.41 % Data as on 19 Nov 24